Publicaciones en las que colabora con Federico Moscardó García (61)

2020

  1. Partial T Cell-Depleted Peripheral Blood Stem Cell Transplantation from HLA-Identical Sibling Donors for Patients with Severe Aplastic Anemia

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 1, pp. 83-87

2019

  1. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

    Leukemia Research, Vol. 76, pp. 1-10

2018

  1. A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

    Annals of Hematology, Vol. 97, Núm. 5, pp. 763-772

  2. Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia (Annals of Hematology, (2018), 10.1007/s00277-018-3229-5)

    Annals of Hematology

  3. Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

    Pharmacogenomics Journal, Vol. 18, Núm. 2, pp. 301-307

2017

  1. Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

    Leukemia and Lymphoma, Vol. 58, Núm. 5, pp. 1197-1206

  2. Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

    Pharmacogenetics and Genomics, Vol. 27, Núm. 7, pp. 270-274

  3. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

    Leukemia and Lymphoma, Vol. 58, Núm. 12, pp. 2880-2894

2016

  1. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia

    Pharmacogenomics Journal, Vol. 16, Núm. 1, pp. 30-40

  2. Positive impact of ABCB1 polymorphisms in overall survival and complete remission in acute myeloid leukemia: A systematic review and meta-analysis

    Pharmacogenomics Journal

  3. Umbilical cord blood transplantation in adults with advanced hodgkin's disease: High incidence of post-transplant lymphoproliferative disease

    European Journal of Haematology, Vol. 96, Núm. 2, pp. 128-135

2015

  1. Bloodstream infections in adult patients undergoing cord blood transplantation from unrelated donors after myeloablative conditioning regimen

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 4, pp. 755-760

  2. Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: A systematic review and meta-analysis of observational studies

    Pharmacogenomics Journal, Vol. 15, Núm. 2, pp. 109-118

  3. Passenger lymphocyte syndrome in liver transplant recipients: A description of 12 cases

    Blood Transfusion, Vol. 13, Núm. 3, pp. 423-428

  4. Transfusion management and immunohematologic complications in liver transplantation: Experience of a single institution

    Transfusion Medicine and Hemotherapy, Vol. 42, Núm. 1, pp. 8-14

  5. Transfusion of ABO non-identical platelets does not influence the clinical outcome of patients undergoing autologous haematopoietic stem cell transplantation

    Blood Transfusion, Vol. 13, Núm. 3, pp. 411-416

2014

  1. A retrospective audit of platelet transfusion in a hematology service of a tertiary-care hospital: Effectiveness of training to improve compliance with standards

    Transfusion and Apheresis Science

  2. Autoimmune cytopenias after umbilical cord blood transplantation in adults with hematological malignancies: A single-center experience

    Bone Marrow Transplantation, Vol. 49, Núm. 8, pp. 1084-1088

  3. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases

    Bone Marrow Transplantation, Vol. 49, Núm. 3, pp. 397-402

  4. Eculizumab for the treatment of pregnancy-related atypical hemolytic uremic syndrome

    Annals of Hematology